Boost Biopharma
Startup
Boost Biopharma provides partners with potent, durable, and broadly neutralizing combinatorial antigens (and proprietary sequences for mRNA vaccines). Boost has developed a complete library of SARS-CoV-2 antigens, which have demonstrated exceptional immune responses in mice and non-human primates when administered intramuscularly, intranasally, and with a variety of adjuvants (and no adjuvants, as well). Our Rapid Antigen Deployment process enables us to generate new antigens that are ready for testing within 14-21 days from sequence identification. Our team also generates novel broadly neutralizing monoclonal antibodies, including the recent development of a broadly neutralizing SARS-CoV-2 mAb (XBB.1.5 binding at 1.1 picomolar) that is currently available for evaluation and license. Boost also works with partners to develop custom antigens and improve our partners' existing candidates.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events